HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Electronic Tracking Success Could End Rx-Only Pseudoephedrine In Mississippi

This article was originally published in The Tan Sheet

Executive Summary

Former Mississippi Gov. Haley Barbour says industry should ask state legislators to repeal the 2010 law that made all PSE drugs Rx-only. CHPA “might get some listeners” if it highlights how the tracking system places less of a financial burden on consumers and the health care system, he says.

You may also be interested in...



States Modify PSE Rx-Only Proposals To Curb Meth Production

Legislators in Kentucky debate requiring a prescription for purchase of OTC pseudoephedrine over monthly and annual limits, while Oklahoma lawmakers consider requiring pharmacists to determine a patient’s need. CHPA opposes further limits on access and promotes electronic tracking with stop-sale technology.

Research Refutes Rx-Only Pseudoephedrine Requirements

Research shows Rx requirements “do not effectively reduce methamphetamine’s overall impact on a given state,” CHPA President Scott Melville says. One study found Oregon’s Rx-only law has not dramatically reduced meth lab incidents compared to other states and the second showed the requirement would cost Oklahoma $59 million annually.

Mississippi PSE Prescription Switch Will Not Start An Avalanche - CHPA

Mississippi lawmakers' decision to make all pseudoephedrine-containing drugs prescription-only will not prompt other states combating methamphetamine to do the same, the Consumer Healthcare Products Association predicts

Related Content

Topics

UsernamePublicRestriction

Register

RS124732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel